Leflunomide (Arava) for adult psoriatic arthritis - horizon scanning review
NHSC
Record ID 32004000885
English
Authors' objectives:
This study aims to summarise the currently available evidence on leflunomide (Arava) for adult psoriatic arthritis.
Authors' recommendations:
Leflunomide is an immunosuppressant disease modifying anti-rheumatic drug (DMARD) that is licensed for psoriatic arthritis (PsA) and rheumatoid arthritis. One small, randomised trial found a statistically significant benefit in terms of PsA activity and joint symptoms and signs.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antirheumatic Agents
- Arthritis, Psoriatic
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.